The features of infectious diseases departments and anti-infective practices in France and Turkey: a cross-sectional study.
The aim of this study was to assess the infectious diseases (ID) wards of tertiary hospitals in France and Turkey for technical capacity, infection control, characteristics of patients, infections, infecting organisms, and therapeutic approaches. This cross-sectional study was carried out on a single day on one of the weekdays of June 17-21, 2013. Overall, 36 ID departments from Turkey (n = 21) and France (n = 15) were involved. On the study day, 273 patients were hospitalized in Turkish and 324 patients were followed in French ID departments. The numbers of patients and beds in the hospitals, and presence of an intensive care unit (ICU) room in the ID ward was not different in both France and Turkey. Bed occupancy in the ID ward, single rooms, and negative pressure rooms were significantly higher in France. The presence of a laboratory inside the ID ward was more common in Turkish ID wards. The configuration of infection control committees, and their qualifications and surveillance types were quite similar in both countries. Although differences existed based on epidemiology, the distribution of infections were uniform on both sides. In Turkey, anti-Gram-positive agents, carbapenems, and tigecycline, and in France, cephalosporins, penicillins, aminoglycosides, and metronidazole were more frequently preferred. Enteric Gram-negatives and hepatitis B and C were more frequent in Turkey, while human immunodeficiency virus (HIV) and streptococci were more common in France (p < 0.05 for all significances). Various differences and similarities existed in France and Turkey in the ID wards. However, the current scene is that ID are managed with high standards in both countries.
Department of Infectious Diseases and Clinical Microbiology, GATA Haydarpasa Training Hospital, Istanbul, Turkey, hakanerdem1969@yahoo.com.
H
H
Erdem
J P
JP
Stahl
A
A
Inan
S
S
Kilic
M
M
Akova
C
C
Rioux
I
I
Pierre
A
A
Canestri
E
E
Haustraete
D O
DO
Engin
E
E
Parlak
X
X
Argemi
D
D
Bruley
E
E
Alp
S
S
Greffe
S
S
Hosoglu
S
S
Patrat-Delon
Y
Y
Heper
M
M
Tasbakan
V
V
Corbin
M
M
Hopoglu
I I
II
Balkan
B
B
Mutlu
E
E
Demonchy
H
H
Yilmaz
C
C
Fourcade
L
L
Toko-Tchuindzie
S
S
Kaya
A
A
Engin
A
A
Yalci
C
C
Bernigaud
H
H
Vahaboglu
E
E
Curlier
D
D
Akduman
A
A
Barrelet
S
S
Oncu
V
V
Korten
G
G
Usluer
H
H
Turgut
A
A
Sener
O
O
Evirgen
N
N
Elaldi
L
L
Gorenek
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000175:diagnosis* / Q000188:drug therapy*; D003430:Cross-Sectional Studies; D005260:Female; D005602:France; D006801:Humans; D017053:Infection Control / Q000379:methods*; D008297:Male; D008875:Middle Aged; D005791:Patient Care / Q000592:standards*; D062606:Tertiary Care Centers; D014421:Turkey
D000900:Anti-Bacterial Agents